Aim: There is an unmet need in Japan for more optimal lipid-lowering therapy (LLT) for patients with homozygous familial hypercholesterolemia (HoFH) who respond inadequately to available drug therapies and/or apheresis, to achieve goals of low-density lipoprotein cholesterol (LDL-C) reduction by 50% or to ＜100 mg/dL.
Efficacy and safety of lomitapide in homozygous familial hypercholesterolaemia: the pan- European retrospective observational study
Marco Bucci;
2021-01-01
Abstract
Aim: There is an unmet need in Japan for more optimal lipid-lowering therapy (LLT) for patients with homozygous familial hypercholesterolemia (HoFH) who respond inadequately to available drug therapies and/or apheresis, to achieve goals of low-density lipoprotein cholesterol (LDL-C) reduction by 50% or to ＜100 mg/dL.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Eur J Prev Cardiol 2021.pdf
accesso aperto
Descrizione: articolo principale
Tipologia:
PDF editoriale
Dimensione
207.52 kB
Formato
Adobe PDF
|
207.52 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
